Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers

Anti-Cancer Drugs

Volumn 8, Issue 9, 1997, Pages 876-885

  Raymond, E ^a   Buquet Fagot, C ^a   Djelloul, S ^a   Mester, J ^a   Cvitkovic, E ^b   Allain, P ^c   Louvet, C ^a   Gespach, C ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Antifolate; Combination chemotherapy; Platinum; Quinazoline

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; NOLATREXED; OXALIPLATIN; THYMIDYLATE SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL SURVIVAL; COLONIC NEOPLASMS; DNA, NEOPLASM; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLATINUM; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0030722949     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199710000-00009     Document Type: Article

References (37)

1. Chancy SG. The chemistry and biology of platinum complexes with 1,2-diaminocyclohexane carrier ligand (review). Int J Oncol 1995; 6: 1291-305.
2. Kidani Y, Inagaki Y, Salto R, Tsukagoshi S. Synthesis and antitumor activities of platinum(II) complexes of 1,2-diaminocyclohexane isomers and their related derivatives. J Clin Hematol Oncol 1977; 7: 197-209.
3. Mathé G, Kidani Y, Segiguchi M et al. Oxalato-platinum or I-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989; 43: 237-50.
4. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6.
5. Ortuzar W, Paull K, Rixe O, Fojo T. Comparison of the activity of cisplatin (CP) and oxaliplatin (Oxali) alone or in combination in parental and drug resistant sublines. Proc Am Ass Cancer Res 1994; 35: A1974.
6. Misset JL, Kidani Y, Gastiaburu J, et al. Oxaliplatinum (I-OHP): experimental and clinical studies. In: Howell SB, ed. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press 1991: 369-75.
7. Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichanel programmable pump. Cancer 1992; 69: 893-900.
8. Extra JM, Espie M, Calvo F, et al. Phase 1 study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
9. Bergerat JP, Green C, Drewinko B. Combination chemotherapy in vitro. Response of human colon carcinoma cells to combination using cis-diamminedichloroplatinum. Cancer Biochem Biophys 1979; 3: 173-80.
10. Piccart MJ, Raymond E, Aapro M, Eisenhauer EA, Cvitkovic E. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer 1995; 31A(suppl 7): 1-10.
11. Ashele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52: 1855-64.
12. Sobrero AF, Aschele C, Guglielmi AP, et al. Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer. Clin Cancer Res 1995; 1: 955-60.
13. Nord LD, Martin DS. Enhancement of thymidylate synthase inhibition. Curr Opin Oncol 1993; 5: 1017-22.
14. Calvette JA, Balmanno K, Taylor GA, et al. Pre-clinical and clinical studies of prolonged administration of the novel thymidylate synthase inhibitor. AG337. 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Ann Oncol 1994; 5: 132 (abstr).
15. Raymond E, Djelloul S, Buquet-Fagot C, Mester J, Gespach C. Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells. Anti-Cancer Drugs 1996; 7: 752-7.
16. Sluyser M. Oncogenes and hormones in mouse mammary tumors. In: Sluyser M, ed. Growth factors and oncogenes in breast cancer. Chichester: Ellis Horwood 1987: 123-41.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 1984; 22: 27-55.
18. Lesuffleur T, Komowski A, Augeron C, et al. Increased growth adaptability to 5-fluorouracil and methotrexate of HT29 suhpopulations selected for their commitment to differentiation. Int J Cancer 1992; 49: 731-7.
19. Andrews PA, Murphy MP, Howell SB. Differential potentiation of alkylating and platinating agent toxicity in human ovarian carcinoma cells by gluthathione depletion. Cancer Res 1985; 45: 6250-3.
20. Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts proposed in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem-Biol Interact 1989; 70: 39-49.
21. Allain P, Berre S, Mauras Y, Le Bouil A. Evaluation of inductively coupled mass spectrometry for the determination of platinum in plasma. Biol Mass Spectrometry 1992; 21: 141-3.
22. Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP. Cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 1459-73.
23. Huang H, Zhu L, Reld BR, Drobny GP, Hopkins PB. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 1995; 270: 1842-4.
24. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M, Brabec V. Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 1991; 20: 267-72.
25. Inagaki K, Kidani Y. Differences in binding of (1,2-cyclohexanediamine)platinum(II) isomers with d(GpG). Inorg Chem 1986; 25: 3-4.
26. Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven PJ. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 1995; 97: 177-84.
27. Van de Vaart PJM, Saris CP, Rietbroek RC, Blommaert FA, Begg AC. Comparison of toxicity, DNA adduct formation and repair for different platinum coordination compounds. Ann Oncol 1996; 7 (suppl 1): 280 (abstr).
28. Tashiro T, Kawada Y, Sakurai Y, Kidani Y, Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum(II): new experimental data. Biomed Pharmacother 1989; 43: 251-60.
29. Raymond E, Chapman W, Woynarowski JM. Mechanism of action of oxaliplatin: effects on cellular DNA. In: Proc 6th Symp on Cancer Research, San Antonio 1996; 48 (abstr).
30. O'Neil CF, Ormerod MG, Robertson D, Titley JC, Cumber-Walseer Y, Kelland LR. Apoptotic and non-apoptotic cell death induced by cis and trans analogue of a novel amine(cycloheamine) dihydroxodichloroplatinum(IV) complex. Br J Cancer 1996; 74: 1037-45.
31. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
32. Scanlon K, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. Pharmacol Ther 1991; 52: 385-406.
33. Johnston PG, Geoffrey F, Drake J, Voeller D, Grem JL, Allegra CJ. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 1996; 32A: 2148-54.
34. Pritchard M, Watson A, Potten C, Jackman A, Hickman J. Inhibition by undine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 1997; 94: 1795-9.
35. Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rythm modulated rate. Eur J Cancer 1993; 29A: 1280-4.
36. Moreau S, Machover D, de Gramont A, et al. Phase II trial of oxaliplatin (L-OHP) in patients with colorectal carcinoma (CRC) previously resistant to 5-fluorouracil (5-FU) and folinic acid (FA). Proc Am Soc Clin Oncol 1993; 12: A645.
37. De Gramont A, Gastiaburu J, Tournigand C, et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 h infusion in pretreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1994; 13: A666.